PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
TI  - Investigational Selective JAK1 Inhibitor Improves Measures of Disease Activity in RA
DP  - 2013 Sep 01
TA  - MD Conference Express
PG  - 18--18
VI  - 13
IP  - 8
4099  - http://mdc.sagepub.com/content/13/8/18.short
4100  - http://mdc.sagepub.com/content/13/8/18.full
AB  - An investigational selective inhibitor of Janus kinase 1 (JAK1) was found to improve clinical endpoints with a favorable safety profile in a Phase 2a dose-ranging study of patients with rheumatoid arthritis (RA). This article discusses the results of a 4-week double-blind, placebo-controlled study of GLPG0634, an orally-available, selective inhibitor of JAK1, in patients with active RA [Vanhoutte FP et al. EULAR 2013 (poster 0229)].